(Press-News.org) Barcelona, Spain – Saturday 30 August 2014: The therapeutic benefit of revascularisation in coronary artery disease (CAD) is emphasised in the 2014 ESC/EACTS revascularisation guidelines presented at ESC Congress by joint Task Force Chairs Professor Stephan Windecker (Switzerland) of the European Society of Cardiology (ESC) and Professor Philippe Kolh (Belgium) of the European Association for Cardio-Thoracic Surgery (EACTS). The joint guidelines are published today on-line in European Heart Journal (1), on the ESC Website (2), in EuroIntervention and in the European Journal of Cardio-Thoracic Surgery.
Previous ESC/EACTS Guidelines on myocardial revascularisation were published in 2010 (3). As part of their update, the Task Force performed a systematic review of the evidence including 100 trials in 93 553 patients with 262 090 patient years in the field of coronary revascularisation. "The key finding was that among patients with stable CAD, coronary artery bypass grafting (CABG) reduces the risk of death, myocardial infarction and repeat revascularisation compared with medical treatment," Professors Kolh and Windecker said.
Professor Windecker said: "It was noteworthy that all stent based coronary revascularisation technologies were found to reduce the risk of repeat revascularisation, whereas new generation drug-eluting stents (DES) but no other percutaneous revascularisation technology improved survival compared with medical treatment"(4).
Following the results of the SYNTAX trial, the importance of this angiographic risk score is summarised and a useful algorithm to calculate the SYNTAX score is included in the document. Revascularisation is recommended based on symptomatic and prognostic indications. As compared with the previous 2010 edition, percutaneous coronary intervention (PCI) now assumes a similar Class and level of evidence as CABG in patients with proximal LAD disease (IA), simple left main disease (Syntax Score32, IIIB). Based on the results of the FREEDOM trial, CABG is now the favoured revascularization therapy among diabetic patients with multivessel CAD and acceptable surgical risk (IA).
The new guidelines favour DES over bare metal stents in nearly all patients and lesion subsets. DES receive a Class I indication among patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. Professor Windecker said: "This upgrade is notable as there was concern about the use of first generation DES in the setting of STEMI but that has vanished with the advent of newer generation DES."
Antithrombotic therapy in revascularisation is the largest chapter and had numerous updates. In patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), pretreatment with prasugrel before PCI is not recommended following the results of the ACCOAST trial. Recommendations on the duration of dual antiplatelet therapy (DAPT) after DES implantation in patients with stable CAD were changed to 6 months.
Professor Windecker said: "The new recommendation recognises that an extension beyond 6 months in patients with stable CAD is no longer necessary."
In patients with STEMI, the use of bivalirudin after PCI has been downgraded from a Class I to a Class IIa recommendation. The Task Force agreed that the lower risk of bleeding observed in HORIZON-AMI is offset at least in part by the higher risk of periprocedural stent thrombosis shown in HORIZON-AMI, EUROMAX, HEAT and BRAVE 4 although there appears to be no impact on mortality and myocardial infarction.
A new chapter on the volume-outcome relationship for revascularisation procedures has been added. It provides the first guidance on minimal numbers of PCI and CABG procedures for physicians and institutions, plus recommendations for training to ensure high quality of care.
Professor Kolh concluded: "Revascularisation requires input from cardiologists, surgeons and interventionalists and our Task Force brought together experts in these fields. We hope the guidelines help clinicians make the best use of the revascularisation techniques currently available and improve quality of care across Europe."
INFORMATION:
ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD
2014-08-30
ELSE PRESS RELEASES FROM THIS DATE:
The early cost of HIV
2014-08-29
Researchers at UC Davis have made some surprising discoveries about the body's initial responses to HIV infection. Studying simian immunodeficiency virus (SIV), the team found that specialized cells in the intestine called Paneth cells are early responders to viral invasion and are the source of gut inflammation by producing a cytokine called interleukin-1 beta (IL-1β).
Though aimed at the presence of virus, IL-1β causes breakdown of the gut epithelium that provides a barrier to protect the body against pathogens. Importantly, this occurs prior to the wide ...
Factor in naked mole rat's cells enhances protein integrity
2014-08-29
SAN ANTONIO (Aug. 29, 2014) — Scientists at the Barshop Institute for Longevity and Aging Studies, part of the School of Medicine at the UT Health Science Center at San Antonio, have found another secret of longevity in the tissues of the longest-lived rodent, the naked mole rat.
They reported that a factor in the cells of naked mole rats protects and alters the activity of the proteasome, a garbage disposer for damaged and obsolete proteins.
The factor also protects proteasome function in human, mouse and yeast cells when challenged with various proteasome poisons, ...
Report advocates improved police training
2014-08-29
A new report released yesterday by the Mental Health Commission of Canada identifies ways to improve the mental health training and education that police personnel receive.
"People with mental illnesses is a prominent issue for Canada's police community, and today's report builds on the increasingly collaborative relationship between law enforcement and people with mental illnesses," says Queen's adjunct professor Dorothy Cotton, a forensic psychologist with an interest in the area of police psychology. "This is a gap-analysis tool that police academy and police services ...
Options for weight loss your primary care doctor might not know about
2014-08-29
NEW YORK – August 29, 2014 - Despite US Preventive Services Task Force recommendations for screening and treating obesity, there are many barriers, several of which may be ameliorated through technological approaches according to a new study by researchers at NYU Langone Medical Center published online August 21, 2014 in the Journal of General Internal Medicine (JGIM).
David Levine, MD, MA, a third year resident in the Department of Internal Medicine at NYU Langone, and colleagues found that compared to usual care, technology-assisted interventions specifically in the ...
Antidepressants show potential for postoperative pain
2014-08-29
After a systematic review of clinical trials based on administering antidepressants for acute and chronic postsurgical pain, researchers have concluded that more trials are needed to determine whether these drugs should be prescribed for postsurgical pain on a regular basis.
Dr. Ian Gilron, a professor and director of clinical pain research in the Department of Anesthesiology, and his team of seven researchers reviewed 15 trials to determine whether the use of antidepressants for pain relief post-surgery would work more effectively than painkillers such as opioids, local ...
Leading Ebola researcher at UTMB says there's an effective treatment for Ebola
2014-08-29
A leading U.S. Ebola researcher from the University of Texas Medical Branch at Galveston has gone on record stating that a blend of three monoclonal antibodies can completely protect monkeys against a lethal dose of Ebola virus up to 5 days after infection, at a time when the disease is severe.
Thomas Geisbert, professor of microbiology and immunology, has written an editorial for Nature discussing advances in Ebola treatment research. The filoviruses known as Ebola virus and Marburg virus are among the most deadly of pathogens, with fatality rates of up to 90 percent. ...
Assortativity signatures of transcription factor networks contribute to robustness
2014-08-29
Dartmouth researchers explored the type and number of connections in transcription factor networks (TFNs) to evaluate the role assortativity plays on robustness in a study published in PLOS Computational Biology in August. The study found that the assortativity signature contributes to a network's resilience against mutations.
"In simulations, it seems that varying the out-out assortativity of TFN models has a greater effect on robustness than varying any of the other three types of assortativity," said Dov A. Pechenick, PhD, lead author and former researcher at the ...
Revealing a novel mode of action for an osteoporosis drug
2014-08-29
Raloxifene is a U.S. Food and Drug Administration (FDA)-approved treatment for decreasing fracture risk in osteoporosis. While raloxifene is as effective at reducing fracture risk as other current treatments, this works only partially by suppressing bone loss. With the use of wide- and small-angle x-ray scattering (WAXS and SAXS, respectively), researchers carried out experiments at the U.S. Department of Energy's (DOE's) Advanced Photon Source (APS) at Argonne National Laboratory that revealed an additional mechanism underlying raloxifene action, providing an explanation ...
Study reveals how Ebola blocks immune system
2014-08-29
Researchers at the Washington University School of Medicine have identified one way the Ebola virus dodges the body's antiviral defenses, providing important insight that could lead to new therapies, in research results published in the journal Cell Host & Microbe.
In work performed at Beamline 19ID at Argonne National Laboratory's Advanced Photon Source, the researchers developed a detailed map of how a non-pathogenic Ebola protein, VP24, binds to a host protein that takes signaling molecules in and out of the cell nucleus.
Their map revealed that the viral protein ...
Argonne scientists pioneer strategy for creating new materials
2014-08-29
Making something new is never easy. Scientists constantly theorize about new materials, but when the material is manufactured it doesn't always work as expected. To create a new strategy for designing materials, scientists at the Department of Energy's Argonne National Laboratory combined two different approaches at two different facilities to synthesize new materials.
This new strategy gives faster feedback on what growth schemes are best, thus shortening the timeframe to manufacture a new, stable material for energy transport and conversion applications.
A recent ...